BMO Capital reiterates a Buy rating on Chemours with a $26 target, citing 32% upside from current levels amid sector adjustments. BMO Capital analyst John McNulty maintained a Buy rating on Chemours (CC) with a $26 price target, aligning with the median Wall Street target
The fund returned 7.89% in Q2 2026, trailing the MSCI World Index's 13.76% gain amid sector disparities. Oakmark Global Fund reported a 7.89% return for Q2 2026, underperforming the MSCI World Index, which delivered 13.76%. Energy and industrials drove performance, while h
The central bank holds rates steady for the sixth consecutive time while revising growth and inflation projections for 2026-2028. The Bank of Canada maintained its benchmark overnight rate at 2.25%, aligning with market expectations. The decision follows six consecutive ho
JPMorgan Chase reported second-quarter net income of $21.2 billion on Tuesday, the highest quarterly profit in the history of U.S. banking, as a surge in stock-trading revenue and a $4.6 billion gain on its Visa stake drove results across every line of business. The report
Chinese automakers' control of the global EV market and declining US EV sales pressure Ford and GM's future profitability. Tesla’s $1.49 trillion market cap surpasses Ford’s $56 billion despite selling fewer than 2 million vehicles, compared to Ford’s 4.5 million. The disp
Phillips 66 remains undervalued despite refining volatility, with Wells Fargo setting a $201 price target amid cost cuts and supply disruptions. Wells Fargo analyst Sam Margolin maintained a Buy rating on Phillips 66 (PSX) and raised the price target to $201, citing long-t
The revised target reflects a lower upside than the median 61% forecast from 10 analysts following Dana's acquisition plans. Deutsche Bank reduced its price target for Dana Inc. (DAN) to $39 from $40 while maintaining a Buy rating, implying a 53% upside from current levels
Jet.AI proposes a $300M reverse takeover with a $10 per share payout, valuing the combined entity at $320M. Jet.AI (JTAI) signed a non-binding letter of intent for a reverse takeover with a private firm valued at approximately $300M. The deal would create a combined compan
H.C. Wainwright lifts HALO price target after J&J's Darzalex Faspro combo reduces death risk by 53% in myeloma trial. H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and raised the price target to $95. The adjustment f
BTIG raised Happen Inc's price target to $25, citing 28% upside potential and improved earnings outlook for specialty finance firms. BTIG increased its price target for Happen Inc. (NASDAQ:HAPN) to $25 from $20, maintaining a Buy rating. The revision implies a 28% upside f
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.